A US court in New Jersey has ruled in favor of Teva Pharmaceutical Industries Ltd. in a chemotherapy drug patent case.
Teva has announced that the US District Court for the District of New Jersey has granted summary judgment in Teva’s favour, ruling that its chemotherapy drug does non-infringe Eloxatin patents held by Sanofi-Aventis. Teva expects that its new chemotherapy medication drug application will receive final approval shortly.
